10-K

The Goldman Sachs Physical Gold ETF (AAAU) filed its annual report on Form 10-K for the fiscal year ended December 31, 2023. The report details the Trust's operations, financial position, and risk factors, emphasizing its objective to reflect the performance of gold's price, less expenses. Key financial highlights include an increase in NAV per share from $17.98 at the end of 2022 to $20.43 at the end of 2023, primarily driven by a rise in gold prices.

Original reporting
Published May 9, 2026, 10:09 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 9, 2026, 10:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$AAAU
Bullish
high confidence
Mentioned
$AAAU
Relevance
6/10
AlphAI data visualization · based on SEC.gov
Decision brief

The 30-second read

$AAAUBullishMed
01

Why it matters

Positive performance signals increased investor interest in gold as a safe haven amid economic uncertainties.

02

Market read

The report underscores the importance of gold in current market conditions, supporting gold-related investment strategies.

03

What to watch

Potential impact of interest rate hikes and geopolitical tensions on gold prices.

Relevance 6/10Timing: short to medium term (next 1-3 months)

Background

The report highlights AAAU's objective to reflect gold's performance, with NAV growth driven by rising gold prices.

Company-level read

Ticker impact

$AAAUBullishHigh confidence
Context

The report pertains to the Goldman Sachs Physical Gold ETF (AAAU), which tracks gold prices.

Expected impact

Potential for continued upward movement in gold-related assets if gold prices remain strong.

Evidence & confidence

The report confirms strong performance aligned with rising gold prices, a key driver for AAAU's NAV growth.

Market effects

Positive outlook for precious metals and gold mining sectors due to sustained gold price strength.

Limited regional impact; primarily affects global gold markets.

High, as gold is a key global asset and inflation hedge.

Counterpoint

Gold prices may experience correction due to macroeconomic factors or dollar strength, potentially reversing recent gains.

Key entities

  • Goldman Sachs

    Issuer of the AAAU ETF and a major global investment bank.

  • Gold

    Underlying asset for AAAU, whose price influences the ETF's NAV.

Related articles

$AAAUMed

Goldman Sachs Physical Gold ETF 3Q 2026: Net income $79.18M — 10-Q Summary

Goldman Sachs Physical Gold ETF (AAAU) reported a 70.1% YoY decline in net income to $79.18M in 3Q 2026. The decrease was driven by a smaller rise in gold's unrealized appreciation, higher realized gains from gold redemptions, and increased sponsor fees. The ETF held 642,797.3 ounces of gold, valued at $2.68B, with a 3.73% quarterly gold price increase. NAV per share rose to $41.16.

$AVGOMed

Why Broadcom Stock Could Double by 2030

Broadcom (AVGO) stock is down 12% YTD but grew Q3 revenue 86% YoY to $29.6B, with AI chip sales tripling. CEO Hock Tan expects AI revenue to double to $115B in 2027 and again to $230B in 2028. Concerns include data center delays and financing risks, but Anthropic's IPO raises $120B, easing worries. Analysts see potential for AVGO stock to double by 2030.

$BRK-BMed

Berkshire Hathaway Stock Jumps 14% in 2026 as Wall Street Downgrades

Berkshire Hathaway's Class B shares rose 13.4% in 2026, closing at $570 on November 20. Argus Research downgraded the stock to 'Hold' from 'Buy,' citing valuation concerns after it surpassed their $550 price target. The company's Q3 operating earnings declined 5.8% YoY to $12.71 billion, while net earnings fell 28% to $22.11 billion. Berkshire's performance contrasts with AI sector downturns, benefiting from its diversified portfolio.

$AVRMedAI 8/10

Anteris Reports Strong One-Year Results For DurAVR Heart Valve In High-Risk Aortic Stenosis Patients

Anteris Technologies (AVR) reported one-year data for its DurAVR heart valve, showing strong performance in high-risk aortic stenosis patients. Key metrics include 1% hospitalization for heart failure, 8.9 mmHg mean pressure gradient, and 96% of patients with mild or no symptoms post-treatment. The study involved 100 patients with complex conditions. Anteris stock closed at $4.99, up to $5.09 in after-hours trading.